|  | Cancer | Lymphoma

Zynlonta (Loncastuximab Tesirine): Antibody-Drug Conjugate Targeting CD19 in B-Cell Lymphoma

Overview

Zynlonta (loncastuximab tesirine-lpyl) is a CD19-directed antibody-drug conjugate (ADC) approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after ≥2 lines of systemic therapy, including DLBCL NOS, high-grade B-cell lymphoma, PMBCL, and FL grade 3B.

Structure & Mechanism

  1. Antibody: Humanized anti-CD19 monoclonal antibody (binds CD19 on B-cells).
  2. Linker: Valine-alanine protease-cleavable linker (stable in circulation, cleaved by lysosomal cathepsins).
  3. Payload: Pyrrolobenzodiazepine (PBD) dimer — DNA cross-linking agent (high potency, sequence-selective).
  4. DAR: ~3 drug molecules per antibody.

Multimodal Mechanism of Action

  1. Targeted delivery: Binds CD19 → internalization → lysosomal cleavage → PBD dimer release → DNA crosslinks → apoptosis.
  2. Bystander effect: Membrane-permeable payload kills neighboring CD19-negative tumor cells and stromal cells.
  3. Immunogenic cell death (ICD): Releases DAMPs (ATP, HMGB1, calreticulin) → activates dendritic cells → primes T-cell response.
  4. ADCC/ADCP: Fc domain engages NK cells/macrophages for antibody-dependent cytotoxicity/phagocytosis.
  5. T-cell modulation: Depletes immunosuppressive regulatory B-cells (Bregs); may enhance T-cell function.

Key Clinical Data (LOTIS-2, Phase 2)

  • ORR: 48.3% (CR 23.8%) in heavily pretreated R/R LBCL (median 3 prior lines; 45% post-CAR-T).
  • Median DOR: 10.3 months (CR: not reached).
  • Median PFS: 4.9 months; OS: 9.5 months.
  • CNS activity: Intracranial responses observed.

Dosing & Administration

  • 150 µg/kg IV over 30 min every 3 weeks (cycle = 21 days).
  • Premedication: Dexamethasone 10 mg IV (reduces edema/effusion), antihistamine, antipyretic.
  • Prophylactic: Ursodiol 300 mg BID (reduces PBD-related hepatic toxicity), antiviral/PCP prophylaxis per institutional guidelines.

Key Toxicities

ToxicityIncidence (All Grade / Grade ≥3)Management
Effusions (pleural, pericardial, ascites)29% / 8%Dexamethasone premed; diuretics; thoracentesis; hold/resume at lower dose
Edema (peripheral, facial)30% / 3%Dexamethasone; compression; diuretics
Elevated GGT / transaminases50%+ / 10%Ursodiol prophylaxis; monitor LFTs q cycle; hold for Grade ≥3
Neutropenia / thrombocytopenia30–40% / 15–20%G-CSF support; dose delay/reduction
Fatigue, nausea, rash, infectionCommonSupportive care

Unique Value

Zynlonta offers a non-chemotherapy, non-cellular option for patients who have exhausted standard therapies, including post-CAR-T. Its multimodal mechanism (direct kill + bystander + immune activation) and manageable safety profile (with prophylactic dexamethasone/ursodiol) make it a valuable addition to the R/R LBCL armamentarium.

Lymphoma - Related Articles